Rivastigmine Transdermal Patch Merging Adhesive and Drug Layers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal patches for Alzheimer's disease treatment, such as Exelon®, require complex preparation processes due to separate drug-containing and adhesive layers, leading to increased time and cost, and long-term oral medication can cause tolerance issues.
Innovation Solution
A transdermal patch design with a drug-containing adhesive layer comprising rivastigmine, a pressure-sensitive adhesive, and skin penetration enhancers, eliminating the need for separate layer preparation and reducing tolerance risks through controlled drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate drug-containing layer and adhesive layer are used, then drug delivery function is improved, but manufacturing complexity increases and preparation time is extended
Solution Approach 1:
The patent combines the drug-containing layer and adhesive layer into a single integrated layer. The adhesive composition includes rivastigmine (10-30 wt%) mixed with pressure-sensitive adhesive polymers, eliminating the need for separate layer preparation while maintaining both drug delivery and adhesive functions through a unified formulation approach
2Reliability
If separate drug-containing layer and adhesive layer are prepared, then drug delivery function is improved, but preparation time and cost increase
Solution Approach 1:
The patent combines the drug-containing layer and adhesive layer into a single integrated layer. The adhesive composition includes rivastigmine (10-30 wt%) mixed with pressure-sensitive adhesive polymers, eliminating the need for separate layer preparation while maintaining both drug delivery and adhesive functions through a unified formulation approach
3Reliability
If oral medication is used for long-term treatment, then treatment effectiveness is maintained, but tolerance develops reducing efficacy
Solution Approach 1:
The patent replaces the oral administration route with transdermal delivery. The rivastigmine is delivered through the skin via a pressure-sensitive adhesive patch, bypassing the gastrointestinal tract and avoiding the tolerance development associated with oral medication, thereby sustaining treatment effectiveness over long-term use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch achieves similar or better skin permeability and bioavailability compared to Exelon®, with simpler manufacturing, reduced tolerance risk, and improved patient compliance, while maintaining effective treatment of Alzheimer's disease.
Implementation Method 1
the adhesive comprises a pressure sensitive adhesive
Implementation Method 2
two kinds of skin penetration enhancers
Data Source
AI summary
The present invention provides a transdermal patch including: a backing layer; a drug-containing adhesive layer including rivastigmine or a pharmaceutically acceptable salt thereof and two kinds of skin penetration enhancers; and a release liner; wherein the drug-containing adhesive layer is disposed between the backing layer and the release liner; a content of rivastigmine or the pharmaceutically acceptable salt thereof is between 10 wt % and 30 wt % based on a total weight of the drug-containing adhesive layer; and the adhesive includes a pressure sensitive adhesive.